Search

Displaying results 3101 - 3110 of 7503 in total
  1. Drug

    Human varicella-zoster immune globulin

    go.drugbank.com/drugs/DB11621
    ApprovedInvestigational

    lack evidence of immunity to varicella and for whom varicella vaccine is contraindicated. … The therapeutic efficacy is proven if administered within 4 days of exposure to varicella zoster virus.

  2. Drug

    Nilotinib

    go.drugbank.com/drugs/DB04868
    ApprovedInvestigational

    A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec

  3. Drug

    Phosphoric acid

    go.drugbank.com/drugs/DB09394
    ApprovedInvestigational

    Phosphoric Acid is a colorless, odorless phosphorus-containing inorganic acid. Phosphoric acid is a sequestering agent which binds many divalent cations, including Fe++, Cu++, Ca++, and Mg++.

  4. Drug

    Sulfur hexafluoride

    go.drugbank.com/drugs/DB11104
    ApprovedInvestigational

    Sulfur hexafluoride is an ultrasound contrast agent indicated for use •in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border

  5. Drug

    Laquinimod

    go.drugbank.com/drugs/DB06685
    Investigational

    Laquinimod is an immunomodulator developed by Active Biotech and produced by Teva Pharmaceutical Industries. … It has been shown to reduce disease activity on magnetic resonance imaging and to be well tolerated orally.

  6. Drug

    Cytisine

    go.drugbank.com/drugs/DB09028
    Investigational

    Recent Phase III clinical trials using Tabex (a brand of Cytisine marketed by Sopharma AD) have shown similar efficacy to varenicline, but at a fraction of the cost. … Recent studies have shown it to be a more effective and significantly more affordable smoking cessation treatment than nicotine replacement therapy.

  7. Drug

    Acadesine

    go.drugbank.com/drugs/DB04944
    Investigational

    It is being developed jointly by PeriCor and Schering-Plough. Acadesine has been granted Orphan Drug Designation for B-CLL in the EU.

  8. Drug

    SLV319

    go.drugbank.com/drugs/DB05077
    Experimental

    SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor.

  9. Drug

    Calanolide A

    go.drugbank.com/drugs/DB04886
    Investigational

    Both drugs are being developed by Sarawak Pharmaceuticals. A preliminary dosing study among HIV-infected individuals showed a significant antiviral effect compared with placebo. … Calanolide A is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) derived from a plant found in the Malaysian rain forest. A related compound, calanolide B, also has anti-HIV activity.

  10. Drug

    Iron sucrose

    go.drugbank.com/drugs/DB09146
    ApprovedInvestigational

    not require dialysis. … Due to less side effects than iron dextran, iron sucrose is more preferred in chronic kidney disease patients.